Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Salarius Pharmaceuticals to hold a conference call » 13:45
06/21/21
06/21
13:45
06/21/21
13:45
SLRX

Salarius Pharmaceuticals

$1.09 /

+0.04 (+3.83%)

CEO Arthur holds a…

CEO Arthur holds a Virtual Key Opinion Leader & Investor Event to discuss Epigenetic Inhibitors for cancer treatment, treating select advanced Sarcomas with Seclidemstat and LSD1 Inhibition for Hematological malignancies on June 21 at 2 pm. Webcast Link

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.09 /

+0.04 (+3.83%)

  • 04
    Mar
  • 30
    Jul
Conference/Events
Salarius Pharmaceuticals to hold a conference call » 09:25
06/21/21
06/21
09:25
06/21/21
09:25
SLRX

Salarius Pharmaceuticals

$1.04 /

-0.045 (-4.15%)

CEO Arthur holds a…

CEO Arthur holds a Virtual Key Opinion Leader & Investor Event to discuss Epigenetic Inhibitors for cancer treatment, treating select advanced Sarcomas with Seclidemstat and LSD1 Inhibition for Hematological malignancies on June 21 at 2 pm. Webcast Link

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.04 /

-0.045 (-4.15%)

  • 04
    Mar
  • 30
    Jul
Over a week ago
Hot Stocks
Salarius Pharmaceuticals announces new clinical trial to study seclidemstat » 07:37
06/15/21
06/15
07:37
06/15/21
07:37
SLRX

Salarius Pharmaceuticals

$1.22 /

+0.045 (+3.83%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals announced the initiation of a clinical trial to investigate seclidemstat, a novel lysine specific demethylase 1 inhibitor, as a potential treatment for hematologic cancers. This investigator-initiated Phase 1/2 trial will be an open label, dose-finding, dose-expansion study to determine the maximum tolerated dose and the safety and tolerability of seclidemstat when used in combination with azacytidine as a treatment for Myelodysplastic Syndromes, or MDS, and Chronic Myelomonocytic Leukemia, or CMML. MDS and CMML are blood cancers that can progress into a deadly form of leukemia, Acute Myeloid Leukemia. The trial was initiated because of compelling preclinical data in which seclidemstat demonstrated anti-proliferative activity across hematologic cancers and synergy when used in combination with azacytidine. The dose-escalation stage of the Phase 1/2 trial will enroll patients aged 18 and older with MDS or CMML. Once MTD of the combination is determined by the Safety Review Committee, the study enters a dose-expansion stage that will enroll additional patients to confirm the safety and tolerability profile for seclidemstat in combination with azacytidine and capture efficacy data regarding overall response rate, duration of response, leukemia-free survival, relapse-free survival, and overall survival.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.22 /

+0.045 (+3.83%)

SLRX Salarius Pharmaceuticals
$1.22 /

+0.045 (+3.83%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
  • 04
    Mar
  • 30
    Jul
Hot Stocks
Salarius Pharmaceuticals presents research data on seclidemstat » 07:56
06/07/21
06/07
07:56
06/07/21
07:56
SLRX

Salarius Pharmaceuticals

$1.20 /

-0.2 (-14.29%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals presented key findings from clinical research involving its lead drug candidate, seclidemstat. These results, disclosed in poster presentations at the American Society of Clinical Oncology Virtual Annual Meeting, included data on seclidemstat's safety, dosing and early efficacy signals in patients with Ewing sarcoma, a rare pediatric bone cancer, and other solid tumors, including FET-rearranged sarcomas. The ASCO Annual Meeting is taking place June 4-8, 2021. Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1, an enzyme that has been shown to play a key role in the development and progression of several cancers. In summary, data presented for the first time during ASCO demonstrated that seclidemstat has a manageable safety profile, favorable pharmacokinetics that support twice-daily oral dosing, and showed evidence of anti-tumor activity in an advanced, heavily pre-treated patient population. In addition, seclidemstat showed no significant hematological toxicities, which can be a limitation for other LSD1 inhibitors. Importantly, single-agent seclidemstat treatment showed signs of drug activity in patients with relapsed/refractory Ewing sarcoma and other advanced cancers, including FET-rearranged sarcomas, also referred to as Ewing-related sarcomas. In patients with FET-rearranged sarcomas, seclidemstat treatment resulted in stable disease and prolonged time to progression suggestive of disease control, a clinically relevant endpoint for soft tissue sarcomas. Poster Title: Phase 1 trial of seclidemstat in patients with relapsed/refractory Ewing sarcoma. Key Information & Findings: For the first time, Salarius is discussing the full findings from the dose-expansion stage of the Phase 1/2, open label study of single-agent seclidemstat in patients with elapsed/refractory Ewing sarcoma. Seclidemstat demonstrated a manageable safety profile with proof-of-concept preliminary activity at or below the recommended Phase 2 dose, established as 900 mg BID. In this heavily pretreated population, a patient dosed at 600 mg BID achieved a reduction in three target lesions after 58 days with further tumor shrinkage after 112 days and 168 days for a maximum 76% tumor shrinkage despite overall progressive disease; Two additional patients dosed at 600 mg BID and 900 mg BID for 56 days demonstrated overall stable disease; Seclidemstat's safety profile is predominantly GI-related with no treatment-related deaths and no significant hematological treatment-related adverse events; Study results warrant further study of seclidemstat in Ewing sarcoma combined with chemotherapy. Poster Title: Preliminary efficacy from an ongoing Phase 1 dose escalation of seclidemstat in patients with advanced solid tumors. Key Information & Findings: This is an ongoing Phase 1/2 open-label, dose-escalation trial assessing single-agent seclidemstat in advanced or recurrent solid tumors. As of April 13, 2021, seclidemstat demonstrated initial activity among advanced sarcoma patients with a manageable safety profile. 7 patients treated for ovarian cancer, prostate cancer and sarcomas achieved stable disease after 56 days with median time to progressionof 4.3 months; patients with advanced FET-rearranged sarcomas demonstrated prolonged SD and prolonged TTP suggestive of disease control, a clinically relevant endpoint for soft tissue sarcoma; As of April 13, 2021, 3 FET-rearranged sarcoma patients demonstrated TTP of 9.4 months, 7.2 months and 4.3 months, respectively; Among 3 patients with FET-translocated sarcomas, prolonged SD greater than 6 months was observed in 2 patients; An elderly patient treated for metastatic extra skeletal myxoid chondrosarcoma, with an aggressive TAF15-CHN translocation, who demonstrated overall SD for 9.4 months has continued therapy and has now been treated for 11 cycles; All 3 FET-translocated patients enrolled in the study showed a TTP that suggests single-agent activity based on a benchmark used to assess novel agent activity for advanced soft tissue sarcomas; Preliminary clinical data supports further exploration in FET-translocated sarcomas, or Ewing-related sarcomas, as a single agent and in a combination therapy. Poster Title: Phase 1 expansion trial of the LSD1 inhibitor seclidemstat with and without topotecan and cyclophosphamide in patients with relapsed or refractory: Key Information: This is an ongoing dose-expansion study assessing seclidemstat at the RP2D in two patient cohorts: a single-agent expansion in select sarcoma patients and a safety lead-in dose escalation and expansion of seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide in Ewing sarcoma patients. The sarcoma cohort will enroll patients with myxoid liposarcoma or other select sarcomas with FET family translocations, including desmoplastic small round cell tumor; the trial will enroll patients treated with one to three prior lines of therapy; The Ewing sarcoma cohort will allow patients treated with up to two prior lines of therapy; Primary objective is safety and tolerability, and secondary objective is efficacy; Recruiting patients across eight U.S. locations

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.20 /

-0.2 (-14.29%)

SLRX Salarius Pharmaceuticals
$1.20 /

-0.2 (-14.29%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
  • 04
    Mar
  • 30
    Jul
Over a quarter ago
Syndicate
Salarius Pharmaceuticals 14.615M share Secondary priced at $1.3685 » 08:33
03/04/21
03/04
08:33
03/04/21
08:33
SLRX

Salarius Pharmaceuticals

$1.60 /

-0.275 (-14.67%)

Ladenburg acted as sole…

Ladenburg acted as sole book running manager for the offering.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.60 /

-0.275 (-14.67%)

SLRX Salarius Pharmaceuticals
$1.60 /

-0.275 (-14.67%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
Syndicate
Salarius Pharmaceuticals announces common stock offering, no amount given » 16:09
03/03/21
03/03
16:09
03/03/21
16:09
SLRX

Salarius Pharmaceuticals

$1.63 /

-0.245 (-13.07%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.63 /

-0.245 (-13.07%)

SLRX Salarius Pharmaceuticals
$1.63 /

-0.245 (-13.07%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
Hot Stocks
Salarius initiates expansion stage of Phase 1/2 trial of seclidemstat » 07:18
02/24/21
02/24
07:18
02/24/21
07:18
SLRX

Salarius Pharmaceuticals

$1.93 /

-0.22 (-10.23%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals announced the initiation of the expansion stage of its ongoing Phase 1/2 clinical trial of seclidemstat in patients with relapsed and refractory Ewing sarcoma and Ewing-related sarcomas, also known as FET-translocated sarcomas. Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1 enzyme, an enzyme that has been shown to play a key role in the development and progression of certain cancers. Per the amended trial protocol, the expansion stage will consist of two treatment arms. The first arm will enroll up to 20 Ewing sarcoma patients and will investigate seclidemstat at the recommended Phase 2 dose in combination with the chemotherapy agents topotecan and cyclophosphamide as a potential second- and third-line therapy for Ewing sarcoma. The second arm will enroll up to 30 patients with Ewing-related sarcomas and will investigate seclidemstat as a single-agent therapy at the RP2D. Both the Ewing and Ewing-related sarcoma arms are designed to evaluate safety and efficacy endpoints, and Salarius expects to report data readouts from the trial towards the end of 2021 and into 2022.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.93 /

-0.22 (-10.23%)

SLRX Salarius Pharmaceuticals
$1.93 /

-0.22 (-10.23%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
SLRX Salarius Pharmaceuticals
$1.93 /

-0.22 (-10.23%)

Hot Stocks
Salarius completes dose-escalation stage of Phase 1/2 trial of seclidemstat » 07:37
02/17/21
02/17
07:37
02/17/21
07:37
SLRX

Salarius Pharmaceuticals

$2.66 /

+0.03 (+1.14%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals announced that it has completed the dose-escalation stage and established the recommended Phase 2 dose for its ongoing Phase 1/2 clinical trial in relapsed/refractory Ewing sarcoma. The Phase 1/2 clinical trial of seclidemstat in patients with Ewing sarcoma was designed as an open-label, multi-center, dose-finding study. The primary objectives of the study were to determine the safety and tolerability of seclidemstat. Secondary objectives were to assess the maximum-tolerated dose, the RP2D, preliminary anti-tumor activity, pharmacokinetics, and pharmacodynamics. Data from patients treated in the dose-escalation portion of the trial demonstrated seclidemstat had a manageable safety profile. The RP2D for the expansion stage has been established and, importantly, PK data from the dose-escalation portion of the trial indicated that treatment at the RP2D achieved plasma concentrations above levels where seclidemstat demonstrated activity in preclinical studies. Salarius is preparing to submit the full findings from the dose-escalation trial, including details on safety, dosing, and initial efficacy signals, for presentation at an upcoming medical conference. Conference embargo rules prevent additional disclosures at this time. Salarius is evaluating its lead drug candidate, seclidemstat, in patients with R/R Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer and in a Phase 1/2 trial enrolling patients with Advanced Solid Tumors. Seclidemstat is a novel, oral reversible inhibitor of the lysine-specific histone demethylase 1 enzyme, an enzyme that has been shown to play a key role in the development and progression of certain cancers. As previously reported, a refractory Ewing sarcoma patient treated with single-agent seclidemstat for six cycles, demonstrated a reduction in prospectively defined target lesions starting at end of cycle 2 with further target lesion tumor shrinkage through end of cycle 4 and cycle 6. The appearance of new non-target lesion at the end of cycle 2 resulted in classification of progressive disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1. Salarius believes this data demonstrates preliminary drug activity in a patient with refractory Ewing sarcoma. Additional data from the dose-escalation portion of the Ewing sarcoma trial has demonstrated further evidence of drug activity, which Salarius hopes to expand upon during the upcoming dose-expansion portion of the trial by treating R/R Ewing sarcoma patients with seclidemstat. In addition to treating R/R Ewing sarcoma patients, the expansion portion of the Phase 1/2 trial will enroll patients with additional select sarcomas that share a similar biology to Ewing sarcoma. Fusions of similar oncogenes to those that are translocated in Ewing sarcoma occur in tumors, such as myxoid liposarcoma, desmoplastic small round cell tumors, and others known as Ewing-related sarcomas or FET-translocated sarcomas. The decision to include Ewing-related sarcoma patients was supported by preclinical data and encouraging clinical data in Salarius' AST trial. Of the small subset of Ewing-related sarcoma patients with progressive disease that enrolled in the AST trial, all patients demonstrated preliminary evidence of seclidemstat drug activity at levels below the RP2D. Encouragingly, in this subset of seclidemstat treated patients, the median time to progression was above the benchmarks established for single-agent activity in the advanced, relapsed soft tissue sarcoma setting. Ewing-related sarcoma patients will continue to be treated with single-agent seclidemstat to generate more safety and early efficacy activity in this patient population. Safety and efficacy results from the AST trial are planned for presentation at an upcoming medical conference. Conference embargo rules prevent further disclosure at this time. This study will continue to evaluate safety and antitumor activity with data readouts expected towards the end of this year and early next year.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$2.66 /

+0.03 (+1.14%)

SLRX Salarius Pharmaceuticals
$2.66 /

+0.03 (+1.14%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
SLRX Salarius Pharmaceuticals
$2.66 /

+0.03 (+1.14%)

Hot Stocks
Salarius Pharmaceuticals receives not in compliance letter from Nasdaq » 08:15
01/21/21
01/21
08:15
01/21/21
08:15
SLRX

Salarius Pharmaceuticals

$1.33 /

+0.125 (+10.37%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals announced that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's Listing Rule 5550 pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.33 /

+0.125 (+10.37%)

SLRX Salarius Pharmaceuticals
$1.33 /

+0.125 (+10.37%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
SLRX Salarius Pharmaceuticals
$1.33 /

+0.125 (+10.37%)

Syndicate
Salarius Pharmaceuticals files to sell 3.96M shares of common stock for holders  17:04
01/15/21
01/15
17:04
01/15/21
17:04
SLRX

Salarius Pharmaceuticals

$1.21 /

+0.05 (+4.31%)

 
ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$1.21 /

+0.05 (+4.31%)

SLRX Salarius Pharmaceuticals
$1.21 /

+0.05 (+4.31%)

06/16/20 Benchmark
Salarius Pharmaceuticals initiated with a Speculative Buy at Benchmark
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Ladenburg
Salarius Pharmaceuticals initiated with a Buy at Ladenburg
  • 30
    Jul
SLRX Salarius Pharmaceuticals
$1.21 /

+0.05 (+4.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.